Nature of business and future operations Tekmira Pharmaceuticals Corporation (the "Company") is a Canadian biopharmaceutical business focused on advancing novel RNA interference therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners.
Under the terms of the agreement, the transaction will be carried out by way of a merger in which OnCore will merge with a wholly-owned subsidiary of Tekmira and thereby become a wholly-owned subsidiary of Tekmira.
Capitalized terms in the chart below shall be read in context to apply to Tekmira Milestone Products; provided, however, that each milestone payment will be payable no more than once in respect of any given Tekmira Milestone Product.
Bruce Cousins - Tekmira Pharmaceuticals Corporation - CFO David, the way we view the transaction certainly the near-term cash needs of the business are provided for with the Tekmira treasury.
Julie Rezler Tekmira Pharmaceuticals Corporation - Director of IR Mark Murray Tekmira Pharmaceuticals Corporation - President and CEO Vivek Ramaswamy OnCore Biopharma, Inc.